4 of brands of infliximab (Remicade, Inflectra, Remisima and Flixabi) are reimbursement in Poland under 6 drug programs. Since the start of the reimbursement in 2012, the funding limit for 1 mg of infliximab has decreased by about 33%, while the volume-weighted average real price
AOTMiT (Polish HTA Agency) is preparing an opinion on the appropriateness of including 32 active substances from 26 limit groups (full list here) ) for reimbursement list for patients over 75 years of age. 90% of drugs containing the mentioned active substances within the analyzed
During the Congress of the Polish Diabetological Association taking place on 24-26 May 2018, a poster will be presented: "Continuous subcutaneous insulin infusion versus multiple daily injections in pregnant women with type 1 diabetes mellitus — a systematic review and meta-analysis of randomised controlled trials
We want to invite all interested to read the article, co-authored by Magdalena Władysiuk, the vice-president of the HTA Consulting: Bioelectrical impedance phase angle as a prognostic indicator of survival in head-and-neck cancer [Full text]
Evidence-based guidelines or clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances*. Polish Ministry of Health decided last year to introduce evidence based approach with AOTMIT (HTA Agency). The AGREE II - Appraisal
Ikarpro.pl - it is an innovative service which combines:quick access to reimbursement databases broad range of analytical tools easy to be found important information.IKAR pro is a platform allowing for quick access to up-to-date data on reimbursed drugs. The platform facilitates complex analyses on reimbursement
In cooperation with the Pulmonology Center in Bydgoszcz (Kujawsko-Pomorskim Centrum Pulmonologii), HTA Consulting is creating a database of patients with respiratory failure - POL-VENT, which participate in the "National program for reducing mortality due to chronic lung diseases by creating rooms for non-invasive mechanical ventilation
HTA Consulting examined the availability and waiting time for reimbursed drugs with orphan status registered by EMA in Poland in 2004-2018 (18/04/2018).Currently in Poland (as of 18/04/2018), 21 innovative medicines with orphan status (out of 104) registered in EMA are reimbursed. 8 of them were
HTA Consulting assessed the availability of orphan drugs with high unmet need (non-oncological drugs, the only one with orphan status registered after 2012 by EMA). Results from 32 countries were obtained - all EU and EFTA countries were analyzed except Cyprus (as of 10/04/2018)Average number
A full program of workshops taking place as part of the upcoming 26th International Student Medical Conference is now available here. HTA Consulting will lead two sessions:The reimbursement process in Poland. Why are some medicines reimbursed and others not? Magdalena Władysiuk Unusual research models. The advanced